Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Inclusion Criteria:

• Histologically confirmed solid tumor, including melanoma or renal cell carcinoma

  • Metastatic or unresectable disease

    • Must have evidence of residual, recurrent, or metastatic disease by radiography

• Measurable disease

  • At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (CT scan, MRI, or x-ray) OR ≥ 10 mm by spiral CT scan
  • Must show clear evidence of disease progression within the lesion if the only site of measurable disease is within a previously irradiated volume
• Standard curative or palliative measures do not exist OR are no longer effective
• No history of or known brain metastases
• Performance status - ECOG 0-1
• At least 3 months
• WBC ≥ 3,000/mm\^3
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• Bilirubin normal
• Creatinine ≤ 1.5 times ULN
• Creatinine clearance ≥ 50 mL/min
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Fasting cholesterol ≤ 350 mg/dL*
• Triglycerides ≤ 400 mg/dL*
• Not pregnant or nursing
• Negative pregnancy test
• Fertile female patients must use effective contraception for ≥ 1 month before, during, and for ≥ 3 months after completion of study treatment (during and for ≥ 3 months after completion of study treatment for male patients)
• No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs
• No ongoing or active bacterial or viral infection
• No psychiatric illness or social situation that would preclude study compliance
• No dementia or altered mental status that would preclude giving informed consent
• No other uncontrolled illnesses
• More than 3 weeks since prior immunotherapy
• Prior biological therapy (e.g., interferon or interleukin 2, vaccine, antibody-based and tyrosine kinase inhibitors) allowed
• No concurrent prophylactic hematopoietic colony-stimulating factors except for epoetin alfa
• No prior cytotoxic chemotherapy
• No prior bryostatin 1, temsirolimus, everolimus, or AP23573 for this malignancy
• More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No concurrent steroids except for topical or inhaled use
• No other concurrent experimental agents
• No prior radiotherapy to > 25% of bone marrow
• More than 3 weeks since prior radiotherapy

• More than 3 weeks since prior major surgery, including nephrectomy

  • Minor surgical procedures allowed
• Recovered from prior therapy
• More than 3 weeks since prior other anticancer investigational agents
• Concurrent CYP3A4 inducers or inhibitors allowed provided patient has been on a stable dose for ≥ 1 week before study entry
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent antineoplastic agents or therapies